

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2009; month=4; day=14; hr=12; min=41; sec=58; ms=275;]

=====

Application No: 10551482 Version No: 2.0

Input Set:**Output Set:**

Started: 2009-03-19 20:37:50.215
Finished: 2009-03-19 20:37:51.188
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 973 ms
Total Warnings: 5
Total Errors: 6
No. of SeqIDs Defined: 6
Actual SeqID Count: 6

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)

SEQUENCE LISTING

<110> Weston-Davies, Wynne

<120> Histamine binding Compounds for Treatment Method for Disease Conditions
Mediated by Neutrophils

<130> 2488-1-011

<140> 10551482

<141> 2009-03-19

<150> PCT/GB2004/001428

<151> 2004-04-01

<150> GB0307544.7

<151> 2003-04-01

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<220>

<221> Xaa

<222> (1) .. (1)

<223> Xaa can be Asp or Glu

<220>

<221> Xaa

<222> (4) .. (4)

<223> Xaa can be Lys or Arg

<400> 1

Xaa Ala Trp Xaa

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Peptide

<400> 2

Asp Ala Trp Lys

1

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<400> 3
Gln Asp Ala Trp Lys
1 5

<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<220>
<221> Xaa
<222> (1) .. (1)
<223> Xaa can be Tyr or Cys

<220>
<221> Xaa
<222> (2) .. (2)
<223> Xaa can be Glu or Asp

<220>
<221> Xaa
<222> (3) .. (3)
<223> Xaa can be Leu or Ile or Phe

<400> 4
Xaa Xaa Xaa Trp
1

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Peptide

<220>
<221> Xaa
<222> (1) .. (1)
<223> Xaa can be Tyr or Cys

<210> 5

<400> 5

Xaa Glu Leu Trp

1

<210> 6

<211> 190

<212> PRT

<213> Rhipicephalus appendiculatus

<400> 6

Met	Lys	Leu	Leu	Ile	Leu	Ser	Leu	Ala	Leu	Val	Leu	Ala	Leu	Ser	Gln	
1				5				10						15		
Val	Lys	Gly	Asn	Gln	Pro	Asp	Trp	Ala	Asp	Glu	Ala	Ala	Asn	Gly	Ala	
			20					25					30			
His	Gln	Asp	Ala	Trp	Lys	Ser	Leu	Lys	Ala	Asp	Val	Glu	Asn	Val	Tyr	
		35					40					45				
Tyr	Met	Val	Lys	Ala	Thr	Tyr	Lys	Asn	Asp	Pro	Val	Trp	Gly	Asn	Asp	
	50					55				60						
Phe	Thr	Cys	Val	Gly	Val	Met	Ala	Asn	Asp	Val	Asn	Glu	Asp	Glu	Lys	
65					70				75						80	
Ser	Ile	Gln	Ala	Glu	Phe	Leu	Phe	Met	Asn	Asn	Ala	Asp	Thr	Asn	Met	
				85					90					95		
Gln	Phe	Ala	Thr	Glu	Lys	Val	Thr	Ala	Val	Lys	Met	Tyr	Gly	Tyr	Asn	
			100					105					110			
Arg	Glu	Asn	Ala	Phe	Arg	Tyr	Glu	Thr	Glu	Asp	Gly	Gln	Val	Phe	Thr	
		115					120					125				
Asp	Val	Ile	Ala	Tyr	Ser	Asp	Asp	Asn	Cys	Asp	Val	Ile	Tyr	Val	Pro	
	130					135					140					
Gly	Thr	Asp	Gly	Asn	Glu	Glu	Gly	Tyr	Glu	Leu	Trp	Thr	Thr	Asp	Tyr	
145				150						155					160	
Asp	Asn	Ile	Pro	Ala	Asn	Cys	Leu	Asn	Lys	Phe	Asn	Glu	Tyr	Ala	Val	
			165					170						175		
Gly	Arg	Glu	Thr	Arg	Asp	Val	Phe	Thr	Ser	Ala	Cys	Leu	Glu			
			180					185					190			